Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Oxigene initiates phase I clinical trials of combretastatin

Nov. 16, 1998

Prolifix and Chugai extend research collaboration

Nov. 16, 1998

Leo's oral vitamin D analogue induces regression, inhibits tumor growth in hepatocellular carcinoma

Nov. 13, 1998

Taiho isolates new antiproliferative agent from Nocardiopsis strain

Nov. 13, 1998

Xenova to begin phase II efficacy trials of XR-5000

Nov. 13, 1998

OSI Pharmaceuticals updates anticancer programs

Nov. 13, 1998

Favorable phase III trial results presented for Evacet at ESMO; company prepares NDA

Nov. 12, 1998

Small-molecule FGFR-1 tyrosine kinase inhibitor with nanomolar potency and good selectivity

Nov. 12, 1998

Protein tyrosine kinase inhibitors for cancer, polycystic kidney disease

Nov. 12, 1998

New anticancer drug candidate revealed by Sugen; product enters phase I testing in U.K.

Nov. 11, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...